Case Study | September 25, 2007

Improved Patient Satisfaction with External Compression Device

Incorporation of Femostop Femoral Compression System into routine hemostasis practice results in early ambulation, low complication rates and high patient satisfaction.

Penn Presbyterian Medical Center is a leader in Philadelphia for cardiac care.


Penn Presbyterian Medical Center, a University of Pennsylvania Health System hospital, is rated one of the top 100 Top Hospitals for cardiovascular care by Solucient — a distinction it has received for five consecutive years. Located in Philadelphia, the 350-bed facility has a long history of providing products and procedures that improve patient care.
One of the more recent developments at Penn Presbyterian Medical Center is the use of the Femostop Femoral Compression System, as opposed to standard manual compression, to achieve hemostasis after a cardiac catheterization procedure. The center has seen a reduction in complication rates and an increase in patient satisfaction as a result of the switch to Femostop.
“Penn Presbyterian Medical Center has always been a leader in the Philadelphia area for cardiac care, so it’s only natural that we have a full product range, including closure devices, that improve patient outcomes and comfort,” stated William Matthai, M.D., clinical associate professor of Medicine at the University of Pennsylvania Medical School and an interventional cardiologist at the hospital. “The Femostop has allowed us to focus more on patient care and less on other tasks, such as manual compression, which the staff here really appreciates.”
The FemoStop Femoral Compression System’s inflatable dome places external, constant and directed pressure on the arterial or venous puncture site after cardiac catheterizations. The system’s belt, along with the specific nature of applied pressure, allow for patient comfort and clinical effectiveness. In addition, because the device is hands-free, it allows the clinician to complete other bedside tasks, while still monitoring the hemostasis process.
The Femostop Instructions For Use demonstrate time to ambulation in a variety of procedures; however, recently published abstracts and studies demonstrate safe, rapid time to ambulation can be achieved with the Femostop in as little as 90 minutes.
“Our own recently published abstracts show that Femostop can be safely and effectively used in diagnostic patients for ambulation in 90 minutes with a high degree of patient safety and with high patient satisfaction at a relatively low cost,” commented Dr. Matthai. “In addition, the Femostop is used at Penn Presbyterian Medical Center after PCI procedures; our own studies show use of the Femostop results in an extremely low incidence of major vascular complications.”
The Femostop can also be used in a variety of other applications, such as large sheath removal with IABPs and pseudoaneurysm repairs.
The center is very pleased with the system and eager to share their experiences. “We have recently finished an educational video demonstrating our use of the Femostop in clinical practice at Penn Presbyterian Medical Center and we are happy to provide information on obtaining this instructional video for interested parties,” Dr. Matthai said.


Related Content

News | Hemostasis Management

October 27, 2021 — Teleflex Inc. announced the completion of patient enrollment in a clinical study evaluating the ...

Home October 27, 2021
Home
News | Hemostasis Management

April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market ...

Home April 21, 2021
Home
Feature | Hemostasis Management | Dave Fornell, Editor

While many cardiac and vascular procedures have largely moved to minimally invasive techniques, the size of these ...

Home March 09, 2021
Home
News | Hemostasis Management

February 8, 2021 — Teleflex Inc. said it recently completed its acquisition of Z-Medica LLC, an industry-leading ...

Home February 08, 2021
Home
News | Hemostasis Management

August 29, 2019 – Merit Medical Systems Inc. announced the U.S. commercial launch of the PreludeSync Evo radial ...

Home August 29, 2019
Home
Technology | Hemostasis Management

February 1, 2019 — Merit Medical Systems Inc. announced that the PreludeSync Distal Compression Device is now available ...

Home February 01, 2019
Home
Videos | Hemostasis Management

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...

Home September 27, 2018
Home
News | Hemostasis Management

August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to ...

Home August 24, 2016
Home
News | Hemostasis Management

January 6, 2016 — The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which ...

Home January 06, 2016
Home
Subscribe Now